James L Hartley
Overview
Explore the profile of James L Hartley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prior I, Hood F, Hartley J
Cancer Res
. 2020 Mar;
80(14):2969-2974.
PMID: 32209560
Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regarding the cancer mutation frequency of Ras, with quoted values varying from 10%-30%. This...
2.
Waters A, Ozkan-Dagliyan I, Vaseva A, Fer N, Strathern L, Hobbs G, et al.
Sci Signal
. 2017 Sep;
10(498).
PMID: 28951536
There is intense interest in developing therapeutic strategies for RAS proteins, the most frequently mutated oncoprotein family in cancer. Development of effective anti-RAS therapies will be aided by the greater...
3.
Waters A, Bagni R, Portugal F, Hartley J
PLoS One
. 2016 Sep;
11(9):e0163272.
PMID: 27684555
Synonymous mutations in the KRAS gene are clustered at G12, G13, and G60 in human cancers. We constructed 9 stable NIH3T3 cell lines expressing KRAS, each with one of these...
4.
Hartley J
Methods Mol Biol
. 2011 Oct;
801:1-12.
PMID: 21987243
Producing recombinant mammalian proteins in native or near-native conformation is fundamental to many aspects of biology. Unfortunately, it is also a task whose outcome is extremely unpredictable. A protein that...
5.
Ganatra M, Vainauskas S, Hong J, Taylor T, Denson J, Esposito D, et al.
FEMS Yeast Res
. 2010 Dec;
11(2):168-78.
PMID: 21166768
Secretion of recombinant proteins is a common strategy for heterologous protein expression using the yeast Kluyveromyces lactis. However, a common problem is degradation of a target recombinant protein by secretory...
6.
Gillette W, Esposito D, Taylor T, Hopkins R, Bagni R, Hartley J
Protein Expr Purif
. 2010 Dec;
76(2):238-47.
PMID: 21146612
Purifying proteins from recombinant sources is often difficult, time-consuming, and costly. We have recently instituted a series of improvements in our protein purification pipeline that allows much more accurate choice...
7.
Kaczmarczyk S, Sitaraman K, Hill T, Hartley J, Chatterjee D
PLoS One
. 2010 Feb;
5(1):e8889.
PMID: 20126275
Shuttling of proteins between nucleus and cytoplasm in mammalian cells is facilitated by the presence of nuclear localization signals (NLS) and nuclear export signals (NES), respectively. However, we have found...
8.
Hartley J, Salehi-Ashtiani K, Hill D
Nat Methods
. 2008 Nov;
5(12):1001-2.
PMID: 19034266
No abstract available.
9.
Hartley J
Curr Protoc Protein Sci
. 2008 Apr;
Chapter 5:5.17.1-5.17.10.
PMID: 18429245
The Gateway cloning method allows a gene to be cloned and subsequently transferred into any vector by in vitro site-specific recombination. It does not necessarily follow, however, that a gene...
10.
Warfield K, Posten N, Swenson D, Olinger G, Esposito D, Gillette W, et al.
J Infect Dis
. 2007 Dec;
196 Suppl 2:S421-9.
PMID: 17940979
Background: Virus-like particles (VLPs) of Ebola virus (EBOV) and Marburg virus (MARV) produced in human 293T embryonic kidney cells have been shown to be effective vaccines against filoviral infection. In...